QM · rank #18 · 2026-09-10
EXENS
PARIS · EUR · $3.32B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +60.61% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +12.7% |
| Profit margin Net profit margin, trailing 12 months. | +6.0% |
| Market cap (USD) Size filter: > $300M required (USD-equivalent). | $3.32B |
| Anchor (recent) Close on 2026-08-11 | $63.55 |
| Anchor (far) Close on 2025-08-11 | $39.57 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Exosens is a French dual-use photonics company supplying high-performance image intensifier tubes, thermal cameras, and digital imaging solutions to defense and surveillance customers across Europe and North America.
Rationale
The 61% trailing momentum is directly underpinned by fundamental delivery — 15.3% H1 2026 revenue growth, 33% EBITDA margins, guidance raised to the upper end, EIB financing secured, and named multi-year contracts (BiNOD, ACTinBlack) providing revenue visibility that validates quality screens rather than mere sentiment rotation.
Material risks
- 1Defense procurement cycle disruption — specifically, a U.S. budget sequestration or continuing resolution that delays BiNOD IDIQ call-offs would hit the single largest named revenue driver and directly invalidate the growth trajectory underpinning both momentum and quality signals.
- 2Export control tightening on advanced night-vision and dual-use photonics (ITAR/EAR escalation) could restrict Photonis Defense's ability to fulfill or expand U.S. Army deliveries and limit the addressable market for EIB-funded capacity expansion, compressing the return on that incremental investment.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.